These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 18505441

  • 1. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T, Takemura G, Kosai K, Ohno T, Takahashi T, Esaki M, Goto K, Maruyama R, Murata I, Minatoguchi S, Fujiwara T, Fujiwara H.
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
    [Abstract] [Full Text] [Related]

  • 2. Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
    Haiping Z, Takayama K, Uchino J, Harada A, Adachi Y, Kura S, Caicun Z, Tsuzuki T, Nakanishi Y.
    Cancer Gene Ther; 2006 Sep; 13(9):864-72. PubMed ID: 16710346
    [Abstract] [Full Text] [Related]

  • 3. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
    Russo LM, del Re E, Brown D, Lin HY.
    Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
    [Abstract] [Full Text] [Related]

  • 4. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.
    Oshima Y, Sakamoto T, Hisatomi T, Tsutsumi C, Ueno H, Ishibashi T.
    Gene Ther; 2002 Sep; 9(18):1214-20. PubMed ID: 12215888
    [Abstract] [Full Text] [Related]

  • 5. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
    Daniel C, Schaub K, Amann K, Lawler J, Hugo C.
    Diabetes; 2007 Dec; 56(12):2982-9. PubMed ID: 17878288
    [Abstract] [Full Text] [Related]

  • 6. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
    Mizuno S, Nakamura T.
    Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
    [Abstract] [Full Text] [Related]

  • 7. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.
    Motomura Y, Kanbayashi H, Khan WI, Deng Y, Blennerhassett PA, Margetts PJ, Gauldie J, Egashira K, Collins SM.
    Am J Physiol Gastrointest Liver Physiol; 2005 Jan; 288(1):G143-50. PubMed ID: 15297261
    [Abstract] [Full Text] [Related]

  • 8. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
    Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y.
    J Am Soc Nephrol; 2004 Oct; 15(10):2637-47. PubMed ID: 15466268
    [Abstract] [Full Text] [Related]

  • 9. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis.
    Sakamoto T, Ueno H, Sonoda K, Hisatomi T, Shimizu K, Ohashi H, Inomata H.
    Gene Ther; 2000 Nov; 7(22):1915-24. PubMed ID: 11127579
    [Abstract] [Full Text] [Related]

  • 10. [Inhibiting scar formation in rat cutaneous wounds by blocking TGF-beta signaling].
    Liu W, Chua CH, Wu XL, Wang DR, Yin DM, Cui L, Cao YL, Longaker MT.
    Zhonghua Yi Xue Za Zhi; 2003 Jan 10; 83(1):31-6. PubMed ID: 12757642
    [Abstract] [Full Text] [Related]

  • 11. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
    Gastinne T, Vigant F, Lavenu-Bombled C, Wagner-Ballon O, Tulliez M, Chagraoui H, Villeval JL, Lacout C, Perricaudet M, Vainchenker W, Benihoud K, Giraudier S.
    Exp Hematol; 2007 Jan 10; 35(1):64-74. PubMed ID: 17198875
    [Abstract] [Full Text] [Related]

  • 12. [Effects of gene therapy with replication-defective adenovirus ericlosing Egr-1 promoter and Smad7 cDNA on irradiation-induced pulmonary fibrosis: experiment with mice].
    Wang L, Feng Y, Fu XL, Cai XW.
    Zhonghua Yi Xue Za Zhi; 2006 Oct 31; 86(40):2847-52. PubMed ID: 17200022
    [Abstract] [Full Text] [Related]

  • 13. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
    Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, Gueler F, Leitges M, Menne J, Haller H.
    Diabetes; 2007 Feb 31; 56(2):346-54. PubMed ID: 17259378
    [Abstract] [Full Text] [Related]

  • 14. Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy.
    Ozawa S, Uchiyama K, Nakamori M, Ueda K, Iwahashi M, Ueno H, Muragaki Y, Ooshima A, Yamaue H.
    Surgery; 2006 Apr 31; 139(4):563-73. PubMed ID: 16627068
    [Abstract] [Full Text] [Related]

  • 15. Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-beta type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds.
    Kushibiki T, Nagata-Nakajima N, Sugai M, Shimizu A, Tabata Y.
    J Control Release; 2006 Feb 21; 110(3):610-7. PubMed ID: 16378654
    [Abstract] [Full Text] [Related]

  • 16. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
    Akahori H, Ota T, Torita M, Ando H, Kaneko S, Takamura T.
    J Pharmacol Exp Ther; 2005 Aug 21; 314(2):514-21. PubMed ID: 15857946
    [Abstract] [Full Text] [Related]

  • 17. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS.
    Exp Clin Endocrinol Diabetes; 2007 Oct 21; 115(9):571-6. PubMed ID: 17943690
    [Abstract] [Full Text] [Related]

  • 18. Influence of C-peptide on early glomerular changes in diabetic mice.
    Maezawa Y, Yokote K, Sonezaki K, Fujimoto M, Kobayashi K, Kawamura H, Tokuyama T, Takemoto M, Ueda S, Kuwaki T, Mori S, Wahren J, Saito Y.
    Diabetes Metab Res Rev; 2006 Oct 21; 22(4):313-22. PubMed ID: 16389646
    [Abstract] [Full Text] [Related]

  • 19. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
    Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H.
    Circulation; 2005 May 17; 111(19):2430-7. PubMed ID: 15867170
    [Abstract] [Full Text] [Related]

  • 20. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis.
    Yamada M, Kuwano K, Maeyama T, Yoshimi M, Hamada N, Fukumoto J, Egashira K, Hiasa K, Takayama K, Nakanishi Y.
    J Clin Pathol; 2007 Aug 17; 60(8):916-20. PubMed ID: 17018685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.